|
(Health-NewsWire.Net, October 21, 2021 )
Market Overview
Point-of-care testing (POCT) is a type of testing in which the analysis is carried out where the patient receives healthcare.
View full report: https://bit.ly/3aWWO3i
Market Dynamics
The factors driving the global neonatal point of care testing market are the rising prevalence of rare diseases and the increasing demand for better healthcare facilities.
The rising prevalence of rare diseases is estimated to drive the neonatal point of care testing market
If known, effective health measures are offered before delivery and during the first week of life, up to two-thirds of neonatal deaths can be avoided. About 3.3 million of the 8.2 million children under the age of five who die each year do so in the neonatal period, or the first four weeks of life.
Neonatal disorders refer to a newborn's natural body, organs, and function being disrupted. Obstetricians have a critical role in reducing newborn problems. Prematurity, respiratory failure, birth trauma, congenital abnormalities, neonatal infection, and infant haemolytic diseases are the most prevalent neonatal ailments.
The importance of preventive obstetrics in decreasing these illnesses cannot be overstated. Prematurity can be avoided with regular antenatal check-ups, a well-balanced diet, iron and folic acid supplements, and avoiding multiple pregnancies.
The oxygen-carrying capacity and oxygen saturation of haemoglobin and cardiac and respiratory function all influence oxygen delivery to the tissues. Hypoxia is linked to pulmonary hypertension, reduced pulmonary blood flow, acidosis, and organ damage.
It can be caused by a lack of cardiac output, congenital heart disease, lung disease, anaemia, or haemoglobin variations. Hyperoxia, which can occur when oxygen is given to a premature baby, has been linked to an increased risk of retinopathy of prematurity and other kinds of oxygen poisoning. The therapeutic goal is to provide adequate oxygen delivery without undue strain on organs like the lungs and retina.
Intensive laboratory testing, including frequent blood gas analysis, is required for preterm, very-low-birth-weight neonates during the first few weeks of life. The weekly blood loss related to phlebotomy for blood testing has been estimated to account for up to 30% of the total blood volume of these tiny, vulnerable newborns.
The anaemia caused by phlebotomy cannot be sustained, and red-cell transfusion is frequently required to treat the anaemia. Blood gas analyzers that use point-of-care testing (POCT) use small sample quantities and hence can reduce the prevalence of phlebotomy-associated anaemia in newborns.
Clinicians in a California neonatal critical care unit were able to measure the influence of a POCT analyzer on the usage of red-cell transfusions after it was introduced. On 100 litres of whole blood, the newly installed POCT analyzer measures blood gases, haemoglobin, hematocrit, sodium, potassium, and ionised calcium all at the same time.
Market Segmentation
By Product
• Instruments
• Assay
By End-User
• Hospitals
• Diagnostic centers
• Maternity & Speciality Clinics
• Other
Download free sample: https://bit.ly/3Egmogj
Geographical Analysis
North America region is estimated to dominate the global neonatal point of care testing market
With the increased childbirths and test approvals, this region is estimated to drive the neonatal point of care testing market. In the U.S overall, about 3.6 million babies were born in 2020. Most babies admitted to the NICU are premature (born before 37 weeks of pregnancy), have a low birth weight (less than 5.5 pounds), or have a medical condition that needs extra attention.
In the United States, around half a million babies are born prematurely. Many of these infants were born with low birth weights. NICU admissions are common for twins, triplets, and other multiples. This is because they are typically born earlier and smaller than single-birth kids. The NICU also provides care for babies with respiratory difficulties, cardiac problems, infections, or birth deformities.
On January 14th, 2019, The Amplatzer PiccoloTM Occluder, the world's first medical device, can be implanted in the tiniest babies, utilising a minimally invasive method to treat patent ductus arteriosus PDA, has been authorised by the US Food and Drug Administration (FDA).
The Amplatzer Piccolo, a device the size of a small pea, now gives hope to premature infants and newborns who require corrective treatment but are resistant to medical treatment and are at high risk of undergoing corrective surgery.
Competitive Landscape
The global neonatal point of care testing market is highly competitive with high demand for newborn screening product launches by key players.
The major key players in the Global Neonatal Point of Care Testing Market are PerkinElmer, Inc., Trivitron Healthcare, Natus Medical Incorporated, Medtronic Plc, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare (General Electric Company), ZenTech S.A., Mp Biomedicals, Baebies, Inc., Masimo, Evancare Medical (Nantong) Co., Ltd., Shenzhen Uni-Medica Technology Co., Ltd. and Shenzhen CAS-Envision Medical Technology Co., Ltd.
Topic's you may be interested, Neonatal Biotinidase Treatment Market, Neonatal Intensive Care Unit Market, Fetal Monitors Market, Neonatal Monitors Market, Fetal and Neonatal Monitoring Devices Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
